



Prescription Monitoring Program Advisory Committee

June 29, 2022

9:00 a.m.

**Texas State Board of Pharmacy
via Zoom**

MINUTES

I. Call to order

Presiding Officer C.M. Schade, M.D., Ph.D., called the meeting to order at 9:01 a.m. The following Committee Members were present:

- A.J. Kirk, M.D., F.F./E.M.T., F.A.A.E.M., F.A.C.E.P.
- Raj Chhadua, R.Ph., Pharm.D.
- Doug Read, R.Ph., Pharm.D.
- Robert Hutchison Jr., R.Ph., Pharm.D.
- Matt Boutte, M.P.A.S., P.A.-C.
- Cherie Holmes-Henry
- Adam Bruggeman, M.D.
- Michael Arambula, M.D., Pharm.D.

TSBP staff present were Timothy L. Tucker, Pharm.D., Executive Director/Secretary; Megan Holloway, General Counsel; Eamon Briggs, Assistant General Counsel; Linda Yazdanshenas, Prescription Monitoring Program (PMP) Manager; and Lily Moreno, Executive Assistant.

II. Announcements

Dr. Schade reported that there were no new announcements.

III. Review of minutes

Dr. Schade called for approval of the minutes from the November 17, 2021 meeting. Dr. Hutchinson made a motion to approve the minutes. The motion was seconded by Dr. Read and approved by all Committee Members.

IV. Presentation by Bamboo Health

Jacob Cooper, Haley Adler, Joe Carhart, and Austin Lehman of Bamboo Health presented information regarding the following:

- PMP metrics, including key performance indicators and other metrics by drug type; and
- NarxCare overdose risk score (v2).

Ms. Adler explained that the following month there would be a delegate reverification for individuals who are required to have a supervising provider associated with their account. Regarding patient look-up requests, Ms. Adler noted a decrease in requests after the time state-funded integration ended.

In response to questions from the committee concerning interstate data sharing and PMP InterConnect, Mr. Cooper explained that states currently not sharing with Texas, except California and Nebraska, are connected to PMP InterConnect and could potentially begin sharing with agreements in place.

Regarding the trend data, Mr. Cooper explained that the issues with the data presented at the previous meeting had been identified and corrected. Additionally, Bamboo Health indicated that for the next meeting the data would be broken down further, including by species code, to help answer questions about the dispensations data.

Presiding Officer Dr. Schade recessed the meeting at 10:58 a.m.

Presiding Officer Dr. Schade reconvened the meeting at 11:21 a.m.

In response to a question from Dr. Read, Mr. Cooper provided information concerning the cost increase for statewide integration and NarxCare.

V. PMP funding update

Dr. Tucker provided an update concerning funding for integration and NarxCare. He reported that, other than the legislative appropriations request, the only potential source for funding still open is the opioid abatement fund. Dr. Tucker explained that the committee in charge of the opioid abatement fund is still in early stages of development and that he has reached out to the committee. Dr. Tucker explained that the cost for integration would be \$3.3 million per year and the cost for NarxCare would be \$400,750 per year. Dr. Schade requested information concerning the general cost for PMP funding.

Committee members expressed concern regarding the cost increase and lack of competition available. Additionally, Dr. Tucker clarified that if another source of funding is not secured and funding is approved through the legislative appropriations request, then the licensees would be responsible for the cost.

VI. PMP surveys discussion

Dr. Schade opened discussion concerning the PMP survey results which were provided to the committee members.

VII. New discussion items to be place on agenda for next meeting


Dr. Kirk requested a discussion regarding an article by Zachary Siegel concerning NarxCare scores. He also requested an opportunity to provide feedback concerning messaging on Texas PMP advertorials.

Presiding Officer Dr. Schade adjourned the meeting at 12:05 p.m.

Approved:



C.M. Schade, M.D., Ph.D.
Presiding Officer



Timothy Tucker, Pharm.D.
Executive Director/Secretary

December 1, 2022